Targeting RAS signalling pathways in cancer therapy.
The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components. Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.
Downward
Julian
J
Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. julian.downward@cancer.org.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015195:Drug Design; D020549:GTP Phosphohydrolase Activators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011905:Genes, ras; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D020549:GTP Phosphohydrolase Activators; D018631:ras Proteins